Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC)-MedSci.cn

Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC)

Lenz, HJ; Ridinger, M; Samuelsz, E; Smeal, T; Ahn, D

ANNALS OF ONCOLOGY, 2022; 33 (7): S718

科室
- - 订阅+
  - 更多科室
工具
服务